A Pilot Clinical Evaluation of Astepro® Nasal Spray for Management of Early SARS-CoV-2 Infection
Status:
Recruiting
Trial end date:
2025-07-01
Target enrollment:
Participant gender:
Summary
The study team proposes to evaluate the efficacy of Astepro® 0.15% nasal spray in treating
SARS-CoV-2 infection in adults through a pilot and feasibility clinical trial at the
University of Chicago.